Last reviewed · How we verify
statin + ezetimibe + Nutraceuticals
This combination reduces LDL cholesterol through dual inhibition of hepatic cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe), supplemented by nutraceuticals with additional lipid-modulating properties.
This combination reduces LDL cholesterol through dual inhibition of hepatic cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe), supplemented by nutraceuticals with additional lipid-modulating properties. Used for Hypercholesterolemia and dyslipidemia management, Cardiovascular risk reduction in patients requiring intensive lipid lowering.
At a glance
| Generic name | statin + ezetimibe + Nutraceuticals |
|---|---|
| Also known as | Anticholesterol drug |
| Sponsor | University of Roma La Sapienza |
| Drug class | Lipid-lowering combination therapy |
| Target | HMG-CoA reductase; NPC1L1 transporter; multiple nutraceutical targets |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Statins inhibit HMG-CoA reductase to decrease endogenous cholesterol production in the liver. Ezetimibe blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter to reduce dietary cholesterol absorption in the intestine. Nutraceuticals (such as plant sterols, red yeast rice, or polyphenols) provide complementary mechanisms to further reduce cholesterol levels and improve cardiovascular risk profiles.
Approved indications
- Hypercholesterolemia and dyslipidemia management
- Cardiovascular risk reduction in patients requiring intensive lipid lowering
Common side effects
- Myalgia or muscle pain
- Elevated liver enzymes
- Gastrointestinal disturbance
- Rhabdomyolysis (rare)
Key clinical trials
- Low Dose Statins, Ezetimibe and Nutraceuticals (PHASE4)
- Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients (PHASE4)
- Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: